PSYCHEMEDICS CORP (PMD) Fundamental Analysis & Valuation

NASDAQ:PMD • US7443752057

Current stock price

2.67 USD
-0.05 (-1.84%)
At close:
2.36 USD
-0.31 (-11.61%)
After Hours:

This PMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PMD Profitability Analysis

1.1 Basic Checks

  • PMD had negative earnings in the past year.
  • In the past year PMD had a positive cash flow from operations.
  • In the past 5 years PMD reported 4 times negative net income.
  • In multiple years PMD reported negative operating cash flow during the last 5 years.
PMD Yearly Net Income VS EBIT VS OCF VS FCFPMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

1.2 Ratios

  • The Return On Assets of PMD (-30.45%) is worse than 84.26% of its industry peers.
  • The Return On Equity of PMD (-54.99%) is worse than 69.44% of its industry peers.
Industry RankSector Rank
ROA -30.45%
ROE -54.99%
ROIC N/A
ROA(3y)-14.19%
ROA(5y)-10.61%
ROE(3y)-25.92%
ROE(5y)-19.89%
ROIC(3y)N/A
ROIC(5y)N/A
PMD Yearly ROA, ROE, ROICPMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

1.3 Margins

  • PMD has a better Gross Margin (38.36%) than 64.81% of its industry peers.
  • In the last couple of years the Gross Margin of PMD has declined.
  • The Profit Margin and Operating Margin are not available for PMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.48%
GM growth 5Y-4.66%
PMD Yearly Profit, Operating, Gross MarginsPMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PMD Health Analysis

2.1 Basic Checks

  • PMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PMD has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for PMD has been reduced compared to a year ago.
PMD Yearly Shares OutstandingPMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
PMD Yearly Total Debt VS Total AssetsPMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M

2.2 Solvency

  • PMD has an Altman-Z score of 0.82. This is a bad value and indicates that PMD is not financially healthy and even has some risk of bankruptcy.
  • PMD has a Altman-Z score of 0.82. This is in the lower half of the industry: PMD underperforms 66.67% of its industry peers.
  • The Debt to FCF ratio of PMD is 1.21, which is an excellent value as it means it would take PMD, only 1.21 years of fcf income to pay off all of its debts.
  • PMD's Debt to FCF ratio of 1.21 is amongst the best of the industry. PMD outperforms 89.81% of its industry peers.
  • PMD has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • PMD's Debt to Equity ratio of 0.09 is fine compared to the rest of the industry. PMD outperforms 74.07% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 1.21
Altman-Z 0.82
ROIC/WACCN/A
WACC9.04%
PMD Yearly LT Debt VS Equity VS FCFPMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

  • PMD has a Current Ratio of 1.59. This is a normal value and indicates that PMD is financially healthy and should not expect problems in meeting its short term obligations.
  • PMD has a better Current ratio (1.59) than 60.19% of its industry peers.
  • A Quick Ratio of 1.59 indicates that PMD should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.59, PMD is in the better half of the industry, outperforming 62.04% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.59
PMD Yearly Current Assets VS Current LiabilitesPMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PMD Growth Analysis

3.1 Past

  • PMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 24.38%, which is quite impressive.
  • The Revenue for PMD has decreased by -11.15% in the past year. This is quite bad
  • Measured over the past years, PMD shows a very negative growth in Revenue. The Revenue has been decreasing by -12.33% on average per year.
EPS 1Y (TTM)24.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.79%
Revenue 1Y (TTM)-11.15%
Revenue growth 3Y1.14%
Revenue growth 5Y-12.33%
Sales Q2Q%-9.21%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMD Yearly Revenue VS EstimatesPMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

Find the best growth stocksShow best growing peers

1

4. PMD Valuation Analysis

4.1 Price/Earnings Ratio

  • PMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMD Price Earnings VS Forward Price EarningsPMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, PMD is valued a bit cheaper than the industry average as 65.74% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 32.63
EV/EBITDA N/A
PMD Per share dataPMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. PMD Dividend Analysis

5.1 Amount

  • PMD has a Yearly Dividend Yield of 12.67%, which is a nice return.
  • PMD's Dividend Yield is rather good when compared to the industry average which is at 0.50. PMD pays more dividend than 99.07% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.88, PMD pays a better dividend.
Industry RankSector Rank
Dividend Yield 12.67%

5.2 History

  • The dividend of PMD decreases each year by -27.43%.
  • PMD has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-27.43%
Div Incr Years0
Div Non Decr Years0
PMD Yearly Dividends per sharePMD Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 0.2 0.4 0.6

5.3 Sustainability

  • 0.03% of the earnings are spent on dividend by PMD. This is a low number and sustainable payout ratio.
DP0.03%
EPS Next 2YN/A
EPS Next 3YN/A
PMD Yearly Income VS Free CF VS DividendPMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M
PMD Dividend Payout.PMD Dividend Payout, showing the Payout Ratio.PMD Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PMD Fundamentals: All Metrics, Ratios and Statistics

PSYCHEMEDICS CORP

NASDAQ:PMD (12/12/2024, 8:24:41 PM)

After market: 2.36 -0.31 (-11.61%)

2.67

-0.05 (-1.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners20.49%
Inst Owner Change0%
Ins Owners12.5%
Ins Owner Change0%
Market Cap15.73M
Revenue(TTM)20.26M
Net Income(TTM)-3.00M
Analysts100
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 12.67%
Yearly Dividend0.14
Dividend Growth(5Y)-27.43%
DP0.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.78
P/FCF 32.63
P/OCF 27.59
P/B 2.89
P/tB 2.89
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY3.06%
OCF(TTM)0.1
OCFY3.62%
SpS3.44
BVpS0.92
TBVpS0.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.45%
ROE -54.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.36%
FCFM 2.38%
ROA(3y)-14.19%
ROA(5y)-10.61%
ROE(3y)-25.92%
ROE(5y)-19.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y18.48%
GM growth 5Y-4.66%
F-Score5
Asset Turnover2.06
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 1.21
Debt/EBITDA N/A
Cap/Depr 6.99%
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.59
Altman-Z 0.82
F-Score5
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)7.85%
Cap/Depr(5y)23.62%
Cap/Sales(3y)0.73%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.79%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.15%
Revenue growth 3Y1.14%
Revenue growth 5Y-12.33%
Sales Q2Q%-9.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-85.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-83.99%
OCF growth 3YN/A
OCF growth 5YN/A

PSYCHEMEDICS CORP / PMD Fundamental Analysis FAQ

What is the fundamental rating for PMD stock?

ChartMill assigns a fundamental rating of 2 / 10 to PMD.


What is the valuation status of PSYCHEMEDICS CORP (PMD) stock?

ChartMill assigns a valuation rating of 1 / 10 to PSYCHEMEDICS CORP (PMD). This can be considered as Overvalued.


Can you provide the profitability details for PSYCHEMEDICS CORP?

PSYCHEMEDICS CORP (PMD) has a profitability rating of 1 / 10.


How financially healthy is PSYCHEMEDICS CORP?

The financial health rating of PSYCHEMEDICS CORP (PMD) is 5 / 10.